

# Javier Fernandez-Ruiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4545248/publications.pdf>

Version: 2024-02-01

196  
papers

13,666  
citations

13854

67  
h-index

25770

108  
g-index

202  
all docs

202  
docs citations

202  
times ranked

9920  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical investigation of Î²-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome. <i>Neuropharmacology</i> , 2022, 205, 108914.	2.0	5
2	Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice. <i>Molecular and Cellular Neurosciences</i> , 2021, 110, 103583.	1.0	16
3	Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2021, 178, 1253-1256.	2.7	3
4	Targeting the CB <sub>2</sub> receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2021, 178, 1373-1387.	2.7	13
5	Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2021, 895, 173875.	1.7	9
6	Inactivation of the CB <sub>2</sub> receptor accelerated the neuropathological deterioration in TDP <sup>43</sup> transgenic mice, a model of amyotrophic lateral sclerosis. <i>Brain Pathology</i> , 2021, 31, e12972.	2.1	13
7	Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's Disease. <i>Molecules</i> , 2021, 26, 3245.	1.7	11
8	(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. <i>Pharmacological Research</i> , 2021, 169, 105492.	3.1	13
9	BiP Heterozygosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12533.	1.8	5
10	Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis. <i>Molecules</i> , 2021, 26, 7643.	1.7	10
11	Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB <sub>2</sub> Receptor**. <i>Chemistry - A European Journal</i> , 2020, 26, 15839-15842.	1.7	20
12	Beneficial effects of the phytocannabinoid Î³ <sup>9</sup> -THCV in L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 141, 104892.	2.1	24
13	Î³ <sup>9</sup> -Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPAR <sup>Î³</sup> and CB <sub>1</sub> receptors. <i>British Journal of Pharmacology</i> , 2020, 177, 4034-4054.	2.7	16
14	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. <i>Scientific Reports</i> , 2020, 10, 4449.	1.6	44
15	Pharmacokinetics of Sativex <sup>Â®</sup> in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. <i>Biomolecules</i> , 2020, 10, 279.	1.8	24
16	Possible therapeutic applications of cannabis in the neuropsychopharmacology field. <i>European Neuropsychopharmacology</i> , 2020, 36, 217-234.	0.3	24
17	Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 602801.	1.4	13
18	Chapter 2. Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System. <i>RSC Drug Discovery Series</i> , 2020, , 10-47.	0.2	0

#	ARTICLE	IF	CITATIONS
19	The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. <i>British Journal of Pharmacology</i> , 2019, 176, 1370-1383.	2.7	41
20	Development of An Oral Treatment with the PPAR- $\delta$ -Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease. <i>Molecules</i> , 2019, 24, 2702.	1.7	21
21	Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives. <i>Frontiers in Pharmacology</i> , 2019, 10, 1284.	1.6	10
22	Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 94.	1.4	12
23	Morphine self-administration alters the expression of translational machinery genes in the amygdala of male Lewis rats. <i>Journal of Psychopharmacology</i> , 2019, 33, 882-893.	2.0	10
24	Targeting glial cannabinoid $CB_2$ receptors to delay the progression of the pathological phenotype in $TDP43$ ( $A315T$ ) transgenic mice, a model of amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2019, 176, 1585-1600.	2.7	46
25	Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 377-386.	1.1	20
26	Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB 1 receptor ligand antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 295-307.	1.4	8
27	Preface: Why a Special Issue on cannabinoid research in Spain?. <i>Biochemical Pharmacology</i> , 2018, 157, 1-7.	2.0	0
28	Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. <i>Biochemical Pharmacology</i> , 2018, 157, 217-226.	2.0	45
29	VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR $\delta$ and $CB_2$ receptor-dependent pathways. <i>British Journal of Pharmacology</i> , 2018, 175, 3813-3831.	2.7	30
30	Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR $\delta$ receptor. <i>Journal of Neuroinflammation</i> , 2018, 15, 19.	3.1	47
31	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. <i>Biochemical Pharmacology</i> , 2018, 157, 67-84.	2.0	75
32	Up-regulation of $CB_2$ receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 551-558.	1.2	46
33	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 398-412.	2.6	15
34	Synthesis of a novel $CB_2$ cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. <i>Journal of Porphyrins and Phthalocyanines</i> , 2017, 21, 67-76.	0.4	4
35	Corrigendum to "Biological characterization of PM226, a chromenoisoxazole, as a selective $CB_2$ receptor agonist with neuroprotective profile" [ <i>Pharmacol. Res.</i> 110 (August 2016) (2016) 205-215]. <i>Pharmacological Research</i> , 2017, 120, 302.	3.1	0
36	Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies. <i>Methods in Enzymology</i> , 2017, 593, 175-198.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 684.	1.8	20
38	Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3. <i>PLoS ONE</i> , 2017, 12, e0176521.	1.1	6
39	Targeting Cannabinoid CB2 Receptors in the Central Nervous System. <i>Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Frontiers in Neuroscience</i> , 2016, 10, 406.	1.4	108
40	The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor- $\beta$ and CB2 pathways. <i>Scientific Reports</i> , 2016, 6, 21703.	1.6	73
41	Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. <i>Pharmacological Research</i> , 2016, 110, 181-192.	3.1	25
42	A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. <i>Journal of Neurology</i> , 2016, 263, 1390-1400.	1.8	105
43	Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. <i>Neuroscience</i> , 2016, 339, 191-209.	1.1	22
44	Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00220.	1.1	13
45	Cannabinoid-dopamine interactions in the physiology and pathophysiology of the basal ganglia. <i>British Journal of Pharmacology</i> , 2016, 173, 2069-2079.	2.7	56
46	VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. <i>Scientific Reports</i> , 2016, 6, 29789.	1.6	61
47	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6753-6771.	2.9	34
48	Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1840-1853.	2.9	12
49	Biological characterization of PM226, a chromenoisoxazole, as a selective CB 2 receptor agonist with neuroprotective profile. <i>Pharmacological Research</i> , 2016, 110, 205-215.	3.1	25
50	Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 66-80.	2.6	18
51	Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 200-208.	2.5	154
52	The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. <i>Addiction Biology</i> , 2015, 20, 773-783.	1.4	34
53	A sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. <i>British Journal of Pharmacology</i> , 2015, 172, 3579-3595.	2.7	58
54	Endocannabinoids and amyotrophic lateral sclerosis. , 2015, , 99-123.		9

#	ARTICLE	IF	CITATIONS
55	Selective, Nontoxic CB <sub>2</sub> Cannabinoid <i>o</i> -Quinone with in Vivo Activity against Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2256-2264.	2.9	33
56	Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB <sub>2</sub> receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 651-667.	2.6	14
57	The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to $\delta^9$ -tetrahydrocannabinol acting through CB <sub>1</sub> receptors. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 505-511.	0.9	30
58	Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. <i>Journal of Neuroimmune Pharmacology</i> , 2015, 10, 233-244.	2.1	44
59	Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. <i>Handbook of Experimental Pharmacology</i> , 2015, 231, 233-259.	0.9	94
60	Altered CB <sub>1</sub> receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. <i>Journal of Psychopharmacology</i> , 2015, 29, 1137-1145.	2.0	8
61	Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. <i>Neurotherapeutics</i> , 2015, 12, 793-806.	2.1	108
62	Identification of CB <sub>2</sub> receptors in human nigral neurons that degenerate in Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 587, 1-4.	1.0	82
63	Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. <i>Drug Design, Development and Therapy</i> , 2014, 8, 263.	2.0	13
64	A restricted population of CB <sub>1</sub> cannabinoid receptors with neuroprotective activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8257-8262.	3.3	136
65	Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of <i>SOD<sup>1</sup>G93A</i> Transgenic Mice and Evaluation of a Sativex <sup>®</sup> -like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 809-815.	1.9	54
66	Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. <i>Neurobiology of Aging</i> , 2014, 35, 2858-2869.	1.5	32
67	Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias. <i>Pathobiology</i> , 2014, 81, 149-159.	1.9	13
68	Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 56-72.	2.6	43
69	Changes in CB <sub>1</sub> and CB <sub>2</sub> receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. <i>British Journal of Pharmacology</i> , 2014, 171, 1472-1489.	2.7	53
70	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. <i>Epilepsia</i> , 2014, 55, 791-802.	2.6	766
71	Targeting CB <sub>2</sub> -GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. <i>Journal of Biological Chemistry</i> , 2014, 289, 21960-21972.	1.6	95
72	Neurodegenerative Disorders Other Than Multiple Sclerosis. , 2014, , 505-525.		4

#	ARTICLE	IF	CITATIONS
73	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. <i>Neuropharmacology</i> , 2013, 75, 155-163.	2.0	57
74	Synthetic cannabinoid quinones: Preparation, inÂvitro antiproliferative effects and inÂvivo prostate antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 111-119.	2.6	42
75	Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 323-333.	1.1	254
76	Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. <i>Archiv Der Pharmazie</i> , 2013, 346, 171-179.	2.1	12
77	Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1708-1716.	1.4	19
78	Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1896-1904.	1.4	34
79	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. <i>Cell Death and Disease</i> , 2013, 4, e862-e862.	2.7	69
80	Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 525-539.	1.2	98
81	Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease. <i>Recent Patents on CNS Drug Discovery</i> , 2012, 7, 41-48.	0.9	64
82	Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntingtonâ€™s Disease: Role of CB<sub>1</sub> and CB<sub>2</sub> Receptors. <i>ACS Chemical Neuroscience</i> , 2012, 3, 400-406.	1.7	81
83	Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. <i>Neuropharmacology</i> , 2012, 62, 2299-2308.	2.0	70
84	Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. <i>Neuroscience Letters</i> , 2012, 508, 67-72.	1.0	13
85	Cannabidiol administration after hypoxiaâ€™ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. <i>Neuropharmacology</i> , 2012, 63, 776-783.	2.0	122
86	A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. <i>Journal of Neuroimmune Pharmacology</i> , 2012, 7, 1002-1016.	2.1	119
87	Chromenopyrazoles: Nonâ€™psychoactive and Selective CB<sub>1</sub> Cannabinoid Agonists with Peripheral Antinociceptive Properties. <i>ChemMedChem</i> , 2012, 7, 452-463.	1.6	27
88	Design and Synthesis of Novel Cannabinoid Ligands Based on a 1,2,3- triazole Scaffold. <i>Letters in Drug Design and Discovery</i> , 2012, 10, 169-172.	0.4	4
89	Symptomâ€™relieving and neuroprotective effects of the phytocannabinoid Î” <sup>9</sup> -THCV in animal models of Parkinson's disease. <i>British Journal of Pharmacology</i> , 2011, 163, 1495-1506.	2.7	158
90	Prospects for cannabinoid therapies in basal ganglia disorders. <i>British Journal of Pharmacology</i> , 2011, 163, 1365-1378.	2.7	98

#	ARTICLE	IF	CITATIONS
91	Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2011, 89, 1509-1518.	1.3	84
92	Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. <i>Brain</i> , 2011, 134, 119-136.	3.7	178
93	Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 2347-2360.	2.5	271
94	Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults. <i>PLoS ONE</i> , 2011, 6, e23690.	1.1	23
95	The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. <i>Neurobiology of Disease</i> , 2010, 37, 434-440.	2.1	222
96	Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. <i>European Journal of Neuroscience</i> , 2010, 31, 1414-1422.	1.2	27
97	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. <i>PLoS ONE</i> , 2010, 5, e11464.	1.1	119
98	The endocannabinoid system as a target for the treatment of neuronal damage. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 387-404.	1.5	78
99	Cannabinoid-Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, e72-91.	1.9	135
100	Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1. <i>PLoS ONE</i> , 2010, 5, e11838.	1.1	118
101	Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration. <i>PLoS ONE</i> , 2009, 4, e5777.	1.1	305
102	The endocannabinoid system in neuropathological states. <i>International Review of Psychiatry</i> , 2009, 21, 172-180.	1.4	30
103	Cannabinoids, multiple sclerosis and neuroprotection. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 645-660.	1.3	13
104	Cannabinoid CB <sub>2</sub> receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. <i>Glia</i> , 2009, 57, 1154-1167.	2.5	165
105	The endocannabinoid system as a target for the treatment of motor dysfunction. <i>British Journal of Pharmacology</i> , 2009, 156, 1029-1040.	2.7	168
106	Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. <i>Brain</i> , 2009, 132, 3152-3164.	3.7	323
107	Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas. <i>Drug and Alcohol Dependence</i> , 2009, 99, 354-358.	1.6	33
108	Cannabinoid CB1 Receptors are Early DownRegulated Followed by a Further UpRegulation in the Basal Ganglia of Mice with Deletion of Specific Park Genes. , 2009, , 269-275.		23

#	ARTICLE	IF	CITATIONS
109	Cannabinoids and Parkinsons Disease. CNS and Neurological Disorders - Drug Targets, 2009, 8, 432-439.	0.8	52
110	Role of CB2 receptors in neuroprotective effects of cannabinoids. Molecular and Cellular Endocrinology, 2008, 286, S91-S96.	1.6	105
111	Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neuroscience Letters, 2008, 438, 10-13.	1.0	35
112	CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology, 2008, 54, 976-988.	2.0	35
113	Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance. Neuroscience, 2008, 153, 687-699.	1.1	16
114	Cannabinoid signaling system. Cell Adhesion and Migration, 2008, 2, 246-248.	1.1	13
115	The Endocannabinoid System in Huntingtons Disease. Current Pharmaceutical Design, 2008, 14, 2317-2325.	0.9	61
116	The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia. , 2008, , 423-483.		14
117	Cannabinoids and Neuroprotection in Motor-Related Disorders. CNS and Neurological Disorders - Drug Targets, 2007, 6, 377-387.	0.8	43
118	Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends in Pharmacological Sciences, 2007, 28, 39-45.	4.0	331
119	Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions. Life Sciences, 2007, 80, 979-988.	2.0	9
120	Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neuroscience Letters, 2007, 421, 270-274.	1.0	73
121	Cannabidiol reduced the striatal atrophy caused by nitropropionic acid <i>in vivo</i> by mechanisms independent of the activation of cannabinoid, vanilloid TRPV <sub>1</sub> and adenosine A <sub>2A</sub> receptors. European Journal of Neuroscience, 2007, 26, 843-851.	1.2	120
122	Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Research, 2007, 1134, 162-170.	1.1	258
123	The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain. Brain Research, 2007, 1145, 48-55.	1.1	13
124	Cannabinoids and Neuroprotection in Basal Ganglia Disorders. Molecular Neurobiology, 2007, 36, 82-91.	1.9	79
125	Preface: Cannabinoids as New Tools for the Treatment of Neurological Disorders. Molecular Neurobiology, 2007, 36, 1-2.	1.9	2
126	UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. European Neuropsychopharmacology, 2006, 16, 7-18.	0.3	70



#	ARTICLE	IF	CITATIONS
127	Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. <i>European Journal of Neuroscience</i> , 2006, 24, 1874-1884.	1.2	49
128	Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB1 receptors. <i>European Journal of Neuroscience</i> , 2006, 24, 3489-3495.	1.2	18
129	Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. <i>Journal of Neurochemistry</i> , 2006, 99, 677-688.	2.1	27
130	Chronic $\delta^9$ -tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 372, 313-317.	1.4	37
131	Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. <i>Brain Research</i> , 2006, 1073-1074, 209-219.	1.1	99
132	Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. <i>Brain Research</i> , 2006, 1107, 199-205.	1.1	34
133	An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments. <i>Current Medicinal Chemistry</i> , 2006, 13, 3705-3718.	1.2	28
134	Endocannabinoids and Dopamine-Related Functions in the CNS. , 2005, , .		0
135	Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. <i>Biochemical Pharmacology</i> , 2005, 70, 446-452.	2.0	81
136	Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. <i>Brain Research</i> , 2005, 1046, 195-206.	1.1	33
137	Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. <i>Brain Research</i> , 2005, 1050, 210-216.	1.1	37
138	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2005, 20, 207-217.	2.1	131
139	Cannabinoid tolerance and dependence: A review of studies in laboratory animals. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 300-318.	1.3	211
140	Therapeutic Potential of the Endocannabinoid System in the Brain. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 609-617.	1.1	13
141	Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. <i>Neurobiology of Disease</i> , 2005, 19, 96-107.	2.1	339
142	Cannabinoids in neurodegeneration and neuroprotection. , 2005, , 79-109.		32
143	Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. <i>British Journal of Pharmacology</i> , 2004, 143, 455-464.	2.7	73
144	In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. <i>European Journal of Pharmacology</i> , 2004, 484, 249-257.	1.7	92

#	ARTICLE	IF	CITATIONS
145	Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. <i>Brain Research</i> , 2004, 1007, 152-159.	1.1	91
146	Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal $\delta^9$ -tetrahydrocannabinol exposure. <i>Cerebellum</i> , 2004, 3, 66-74.	1.4	39
147	Effects of Neonatal Exposure to Methamphetamine: Catecholamine Levels in Brain Areas of the Developing Rat. <i>Annals of the New York Academy of Sciences</i> , 2004, 1025, 602-611.	1.8	18
148	Cannabinoids and gene expression during brain development. <i>Neurotoxicity Research</i> , 2004, 6, 389-401.	1.3	101
149	Transthyretin is involved in depression-like behaviour and exploratory activity. <i>Journal of Neurochemistry</i> , 2004, 88, 1052-1058.	2.1	111
150	Behavioral and molecular changes elicited by acute administration of SR141716 to $\delta^9$ -tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. <i>Drug and Alcohol Dependence</i> , 2004, 74, 159-170.	1.6	62
151	Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. <i>NeuroReport</i> , 2004, 15, 2375-2379.	0.6	57
152	Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. <i>Addiction Biology</i> , 2003, 8, 159-166.	1.4	34
153	Prenatal cannabinoid exposure and gene expression for neural adhesion molecule L1 in the fetal rat brain. <i>Developmental Brain Research</i> , 2003, 147, 201-207.	2.1	46
154	Effects of perinatal exposure to $\delta^9$ -tetrahydrocannabinol on operant morphine-reinforced behavior. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 577-584.	1.3	38
155	Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2003, 84, 1097-1109.	2.1	133
156	Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 403-412.	2.6	42
157	Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake: A Comparison with Effects on Fatty Acid Amidohydrolase. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1512-1522.	2.9	83
158	Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. <i>NeuroReport</i> , 2003, 14, 813-816.	0.6	66
159	The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. <i>Life Sciences</i> , 2002, 70, 1407-1414.	2.0	56
160	Endocannabinoids and basal ganglia functionality. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 257-267.	1.0	52
161	Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels. <i>Drug and Alcohol Dependence</i> , 2002, 66, 77-84.	1.6	127
162	UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. <i>European Journal of Pharmacology</i> , 2002, 449, 99-103.	1.7	63

#	ARTICLE	IF	CITATIONS
163	The endogenous cannabinoid system and the basal ganglia. , 2002, 95, 137-152.		126
164	Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Research, 2002, 929, 236-242.	1.1	107
165	Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research, 2002, 954, 73-81.	1.1	253
166	Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of $\delta^9$ -Tetrahydrocannabinol-Tolerant Rats. Journal of Neurochemistry, 2002, 74, 1627-1635.	2.1	144
167	Blockade of cannabinoid CB1 receptor function protects against <i>in vivo</i> disseminating brain damage following NMDA-induced excitotoxicity. Journal of Neurochemistry, 2002, 82, 154-158.	2.1	76
168	Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 2002, 44, 23-35.	0.6	114
169	Exposure to cannabinoids in the development of endogenous cannabinoid system. Neurotoxicity Research, 2002, 4, 363-372.	1.3	16
170	Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to $\delta^9$ -tetrahydrocannabinol. Neurotoxicity Research, 2002, 4, 211-218.	1.3	20
171	Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotoxicity Research, 2002, 4, 601-608.	1.3	32
172	Prenatal Exposure to Methamphetamine in the Rat. Annals of the New York Academy of Sciences, 2002, 965, 68-77.	1.8	14
173	Endocannabinoid Transporter Inhibitors. Current Medicinal Chemistry - Central Nervous System Agents, 2002, 2, 129-141.	0.6	8
174	Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 4505-4508.	2.9	69
175	Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport, 2001, 12, 2125-2129.	0.6	91
176	Increased cannabinoid CB1receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. European Journal of Neuroscience, 2001, 14, 1827-1832.	1.2	166
177	Changes in cannabinoid CB1receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse, 2001, 41, 195-202.	0.6	62
178	Effects of cannabinoids on adrenaline release from adrenal medullary cells. British Journal of Pharmacology, 2001, 134, 1319-1327.	2.7	44
179	Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. European Journal of Pharmacology, 2001, 420, 123-131.	1.7	113
180	Neonatal Methamphetamine in the Rat: Evidence for Gender-specific Differences upon Tyrosine Hydroxylase Enzyme in the Dopaminergic Nigrostriatal System. Annals of the New York Academy of Sciences, 2000, 914, 431-438.	1.8	17

#	ARTICLE	IF	CITATIONS
181	Prenatal $\delta^9$ -tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. <i>Developmental Brain Research</i> , 2000, 120, 77-81.	2.1	44
182	Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. <i>Brain Research</i> , 2000, 857, 56-65.	1.1	55
183	Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. <i>Pituitary</i> , 2000, 3, 221-227.	1.6	16
184	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. <i>Biochemical and Biophysical Research Communications</i> , 2000, 270, 260-266.	1.0	172
185	The endogenous cannabinoid system and brain development. <i>Trends in Neurosciences</i> , 2000, 23, 14-20.	4.2	303
186	Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. <i>Life Sciences</i> , 2000, 66, 485-494.	2.0	100
187	Uso de los cannabinoides a trav�s de la historia. <i>Revista De Psicolog�a De La Salud</i> , 2000, 12, 19.	0.2	7
188	Sistema cannabinoide end�geno: ligandos y receptores acoplados a mecanismos de transducci�n de se�ales. <i>Revista De Psicolog�a De La Salud</i> , 2000, 12, 59.	0.2	1
189	Perinatal $\delta^9$ -Tetrahydrocannabinol Exposure Augmented the Magnitude of Motor Inhibition Caused by GABA B , but not GABA A , Receptor Agonists in Adult Rats. <i>Neurotoxicology and Teratology</i> , 1999, 21, 277-283.	1.2	47
190	Pharmacological and biochemical interactions between opioids and cannabinoids. <i>Trends in Pharmacological Sciences</i> , 1999, 20, 287-294.	4.0	364
191	Cannabinoid receptor and WIN-55,212-2-stimulated $[^{35}S]GTP\gamma S$ binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. <i>Neurochemistry International</i> , 1999, 34, 473-482.	1.9	23
192	Time-dependent differences of repeated administration with $\delta^9$ -tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by $\delta^4$ -opioid and CB1-cannabinoid receptors in the caudate-putamen. <i>Molecular Brain Research</i> , 1999, 67, 148-157.	2.5	61
193	Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. <i>Life Sciences</i> , 1999, 65, 327-336.	2.0	51
194	Role of endocannabinoids in brain development. <i>Life Sciences</i> , 1999, 65, 725-736.	2.0	100
195	Identification of Endocannabinoids and Cannabinoid CB <sub>1</sub> Receptor mRNA in the Pituitary Gland. <i>Neuroendocrinology</i> , 1999, 70, 137-145.	1.2	78
196	Effects of perinatal exposure to $\delta^9$ -tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. <i>Journal of Molecular Neuroscience</i> , 1996, 7, 291-308.	1.1	69